Delavan, WI – May 22, 2024 – PlantPharm BioMed, Ltd., a leading-edge biotechnology research organization, announced today that Dr. Richard Matner - President, will speak at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California. Dr. Matner will speak to senior biotech executives, business development leaders and investors to introduce PlantPharm BioMed, and discuss the work they are doing to develop a feed-based SARS-CoV-2 vaccine for animals.  The presentation will take place on Monday, June 3 at 3:30pm in the Company Presentation Theater 2.

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day event includes networking, programming and partnering opportunities.

PlantPharm BioMed has been working to develop an edible vaccine to address zoonotic transmission of SARS-CoV-2 between animals and humans.  The edible vaccine will help break the animal-related path of the pandemic chain of COVID-19 by vaccinating animals of multiple species whether wild or domestic, with oral, solid dose pellets mixed into feed stations. 

The project is funded through a collaborative agreement from USDA APHIS (The U.S. Department of Agriculture, Animal and Plant Health Inspection Service).  PlantPharm BioMed was chosen for this award as it supports the actions of APHIS toward the world-wide “One Health initiative” - a concept that recognizes that the health of people, animals and the environment are linked. 

APHIS is currently conducting multiple projects related to One Health, including those aimed at understanding how the SARS-CoV-2 virus behaves in different animals, how it moves between animals and people, and what we can do to interrupt the chain of transmission.  APHIS, PlantPharm BioMed, and the One Health initiative will utilize the findings from these collective studies to help prevent or reduce the impact of future zoonotic disease outbreaks.

PlantPharm BioMed has invested more than 30 years conducting research on the controlled environment growth of gene-edited plants leading to the Company’s proprietary technology and ability to create low-cost and effective plant-grown biopharmaceuticals and solid dose, oral vaccines.  The Company’s technology has been demonstrated in a successful FDA-approved human clinical trial of an orally administered plant-based Hepatitis B vaccine grown in plants.

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the  BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Good Day BIO is the only daily newsletter at the intersection of biotech, politics, and policy. Subscribe here.